Mr. Hyukjong Lee is an entrepreneur and a leader in the pharmaceutical and biopharmaceutical industry with more than 20 years of experience. He is currently the CEO and President of Binex which is known to be one of the top biologics CDMO in Asia where he has been in charge of corporate strategy planning and global business development, etc. He is the co-founder of Binex Holdings, the largest shareholder of Binex. Prior to his career at Binex, he has mainly been responsible for strategy planning and business development as the CEO at Genexine from 2005 to 2011. He is also an expert in the finance field with experience at Daewoo Securities.
Mr. Hyukjong Lee holds a B.A. in Business Administration, a M.A. in Finance at Seoul National University, and a Master of Business Administration (MBA) at Haas School of Business, University of California Berkeley.

Dr. Pai Jin Keon graduated from the Department of Biochemistry of Yonsei University in 1974 and received Ph.D. at the School of Pharmacy, the University of Wisconsin-Madison, in 1982. Since 1986 Dr. Pai has worked as a senior researcher at Schering-Plough in the United States for 24 years.
Since returning to Korea in 2008, he served as Executive Director of R&D, JW Pharmaceutical Co., Ltd., and CEO of C&C New Drug Development Research Institute. Dr. Pai was essential in introducing open innovation at Handok Pharmaceuticals for five years. After retiring at Handok, he was the Vice President of the Abnoa Research Institute in Korea. He currently serves as the Senior Vice President of Innocure Therapeutics and an in-house board director. He is also helping startups as the head of the Technology Assessment Team at the WoojungBio New Drug Discovery Cluster.
He published 'Development of New Medicine to Save People' and 'Basic Story of Saving People in COVID-19' and has written more than 400 columns for ordinary people.

Peter N. Laivins is an Independent consultant and Founder of Neurocognitive Insights LLC. An experienced executive with integrity and proven leadership of both commercial and clinical development for emerging biotech and large pharma, provides c-suite level advice to leaders of growth-oriented companies.
Most recently, Peter served as Chief Commercial Officer for Alzheon Inc., a privately-held neuroscience company, overseeing strategy, communications, and investor development. Prior to Alzheon, as Senior Vice President of Strategic development program leadership in R&D at Tesaro Inc., he led development core teams for the PARP-inhibitor ZEJULA© and multiple immuno-oncology assets (anti-PD1, anti-TIM3, and anti-LAG3).
At Merrimack Pharmaceuticals, as Senior Vice President - Late-stage clinical development, he was responsible for the phase 3 development and FDA approval of ONIVYDE© - the first new therapy for metastatic pancreatic cancer in 20 years.
During a 20+ year tenure at Pfizer Inc., Peter held roles of increasing responsibility culminating as Senior Director / Group Leader, Pfizer US Oncology, where he built a cross-functional oncology business unit and led the launch of SUTENT© - a breakthrough oral tyrosine kinase inhibitor for renal cell carcinoma. A graduate of McGill University (Montreal) with a BSc in microbiology and immunology, and MBA in marketing and corporate policy, originally from Montreal Canada, Peter now resides in Scituate Massachusetts, USA.
Through integrity and diversity of leadership experience across the spectrum of research, development and commercialization, we believe that Peter Laivins brings a powerful combination of skills qualifying him as a Board member for Genexine.

Mr. Warma is President and CEO of Genexine, Inc. He is leading the commercialization of its lead assets and its global expansion. Previously, Mr. Warma was the General Manager of IMab Biopharma U.S., a global biopharmaceutical company where he was responsible for the expansion of global operations and a key driver in I-Mab’s U.S. IPO.
Prior to that, Mr. Warma was President and CEO of Opexa Therapeutics, Inc., a publicly traded biopharmaceutical company developing novel cellular therapies for autoimmune diseases, and CEO of Viron Therapeutics, a private biotechnology company developing novel protein-based therapeutics for cardiovascular disease and transplantation.
Mr. Warma spent several years in key management roles at Novartis Pharmaceuticals at its corporate headquarters in Basel, Switzerland in Global Marketing and as Head of International Pharma Policy. He obtained an honors Bachelor of Science degree specializing in neuroscience from the University of Toronto and an International MBA from the Schulich School of Business at York University in Toronto.

Jungwon is a president and executive board member of Genexine, and she is responsible for all of the R&D-related divisions of the company, such as the Bio Research Institute and Clinical Development teams.
Prior to Jungwon joining Genexine in 2013, she was a senior researcher at the Samsung Biomedical Research Institute and the Institute of Autoimmunity at the Catholic University of Korea. Since 2013 she took a leading role as a senior researcher in the Clinical Development team at Genexine and later became head of R&D. She has been managing various important pipeline developments and led important R&D decisions as an R&D head.
Jungwon studied at the College of Pharmacy, Seoul National University, and researched at the Bio-Technology Institute of the University of Minnesota and Channing laboratory of Harvard Medical school as a post-doctoral fellow.

Sung June is an executive board member of Genexine, and he is responsible for all managerial support functions of the company, including financial strategy, accounting, investor and public relations, legal and SCM.
Sung June previously served as President and COO of ROKIT Healthcare, where he supervised all managerial functions of the company. Before joining ROKIT, Sung June was CFO at Handok, Schneider Electric and Nike Korea. He began his professional career as a certified public accountant at Arthur Andersen.
Sung June holds an MBA and BA in Business Administration from Yonsei University. He also received an LLM from Vanderbilt Law School. Sung June is a member of KICPA, AICPA, and New York Bar.

Yonsei University with a degree in biochemistry, Dr. Sung received his Ph.D. in molecular biology from the University of Minnesota in the United States and worked as a researcher at the Department of Pathology at Harvard Medical School.
In July 1989, he began his professorship at the Department of Life Science in Pohang University of Science and Technology and continued in this position until June 1999, when he founded Genexine and the company has subsequently grown to be a leading biotech company in KOSDAQ today.

• Head Director of Postech Univ. Life Science Center
• Head Director of Postech-Catholic Univ. Bio Medica Institute
• Ph.D. Molecular Biology, University of Minnesota
• Harvard Univ. researcher

Professor of Medicine, Seoul St. Mary’s Hospital Director in Medical Oncology Program, the Catholic University of Korea

Professor Jin Hyoung Kang graduated from The Catholic University of Korea in 1984 and took an internship and residency in Internal Medicine at St. Mary’s Hospital between 1984 and 1988. He earned his MS in 1988 and Ph.D. in 1995 at The Catholic University Graduate School. He was a research fellow at Cornell University Medical College, majoring in research on cell adhesion molecules in tumor metastasis. He has been a faculty member of Internal Medicine, The Catholic University of Korea since 1993 and a Professor of Medical Oncology since 2004. In 2018, He earned a master’s degree in EMBA Program at Korea Management Business School.
He has published more than 280 articles in peer-reviewed journals. His current research focus is experimental therapeutics and early clinical development of novel target agents and immune-oncology drugs. He discovered a novel driver oncogene, KIF5B-RET, in a Korean NSCLC patient in 2012 and is currently interested in autophagy and tumor microenvironment in cancer research.
Professor Kang has been involved in clinical trials as principal investigator or co-investigator in over 120 clinical trials evaluating novel agents in other malignancies, including lung cancer, head and neck cancer, and malignant melanoma. He is trying to construct a prediction model applying deep learning techniques to multi-omics data curated from lung cancer patients.
Professor Kang has contributed to evaluating novel anti-cancer drugs and the bioequivalent test of generic drugs as an Executive Consultant of MFDS since 2002. He is carrying out the R&D Projects funded by KNCC (Korean National Cancer Center, Cancer Conquer Project) and NRF (National Research Foundation). He was the president of the Korean Cancer Study Group (KCSG) between 2016 and 2021. Currently, he is the Korean Head and Neck Cancer Association president and a member of international scientific societies, including ASCO, AACR, ESMO, and IASLC.

Mr. Kang has more than 30 years of experience in the healthcare and pharmaceutical industry. His career started in 1987 at Dong-A Pharmaceutical Co., where he was CEO in the last position. As an executive in Dong-A, he served in numerous functions, including marketing, product development, strategic planning, and R&D planning. He also served as Vice Chairman of the Korea Pharmaceutical Manufacturers Association. He holds a BS from Seoul National University, a Master of Science in Industrial Engineering from Stanford, and an MBA from Harvard. He advised many M&A transactions recently and invested in various biotech ventures, including Access Bio, Pharmgen Science, Oncopep, and Phycoilbiotech.

Dr. Myeong-Hee Yu is a research scientist emeritus at KIST (Korea Institute of Science and Technology). She serves as the Chief Science Officer of Bertis, Inc., a proteomics-based diagnostic company. She has spent over 35 years working on the structure-function relationship of proteins. In her early scientific carrier, Dr. Yu had studied the protein folding process mainly focusing on how genetic emphysema, a human disorder resulting from alpha-1-antitrypsin deficiency, is associated with a hepatic block in the protein folding process. Since July 2002, Dr. Yu has devoted herself to establish the national infrastructure in Korea of proteomics technology, an emerging omics technology after the Human Genome Project, and had been the Director of Functional Proteomics Center, one of 21C Frontier R&D Initiatives of the Ministry of Science and Technology. She also developed international collaboration with the Office of Cancer Clinical Proteomics Research (Director: Dr. Henry Rodriguez) at NCI, which resulted in an MOU regarding collaboration in proteomics research between NCI and KIST Functional Proteomics Center in 2009. In 2016 the second MOU was signed to facilitate scientific and programmatic collaborations between the two institutes in clinical proteogenomic studies and their translation to care, which had established the current International Cancer Proteogenome Consortium (ICPC).
Dr. Yu received Ph.D. at the University of California, Berkeley (1981) and had postdoctoral training at M. I. T. Dr. Yu was appointed as the Senior Secretary to the President of Korea for national future strategy, and had served the position till February 2013. Dr. Yu had been the President of KOGO (The Korean Genome Organization), The Korean Biophysics Society, and KSBMB (Korean Society for Biochemistry and Molecular Biology). She has been a member of The National Academy of Science and Technology since 2002 and a member of The National Academy of Engineering of Korea since 2014.
She has earned numerous national and international awards including L'OREAL- UNESCO for Women in Science International Award (1998), Seoul City Cultural Award from Seoul City (2001), and Order of Science and Technology, Ungbi Medal, from Korean Government (2004). She was elected as one of 60 Women in 60 Years History of UNESCO (2006).

Dr. Mi-Chung Ahn is an immunologist, a patent attorney, and CEO of SL Bigen, one of the leading Bio-venture in Korea, focusing on gene therapeutics via novel multi-engineered MSC and NK cell lines. Over 25 years, Dr. Ahn has developed a diverse career in the biopharmaceutical industry. She holds an M.S. in Microbiology from the University of Illinois and a Ph. D in Immunology from Rush University in Chicago. Dr. Ahn started building her career as a government officer at the Ministry of Industry, mainly in charge of developing long-term national R/D projects. She moved to the Korean Intellectual Property Office to experience IP Tribunal and Patent Judge in the field of the biopharmaceutical industry for ten years. Before joining SL Bigen, Dr. Ahn worked at the ERUUM & LEEON IP Law firm as a founder and managing partner, focusing on the broad spectrum of IP services and Tech-transfer consultation for 15 years. Besides, Dr. Ahn has been a BOD member in Genexine from 2015 to 2019.

Shin was the Director of the Brain Science Institute, KIST, and then the Director of the Center for Cognition and Sociality, IBS. He continues his research as an Honorary Fellow of IBS. He serves as a CSO at SL Bigen Co. (Ltd.).
He has been using molecular genetics to study neural mechanisms for animal behaviors, primarily focusing on the role of the thalamus in normal and diseased brains. His interest was in the regulation of intracellular Ca2+ levels in brain cells. He utilized gene knock-out tools on genes such as voltage-gated Ca2+ channels and PLC enzymes. Beginning in 2010, his research interest has evolved to the neurobiology of social behaviors. He has pioneered the establishment of a behavioral paradigm, observational fear learning in mice, a rodent model for emotional contagion, and the basic form of affective empathy. This paradigm allowed, for the first time, to study affective empathy at the molecular and cellular levels.
His contribution to science has been recognized globally by multiple honors, including being elected to the National Academy of Science, Republic of Korea, a foreign member at the National Academy of Science, USA, and an AAAS Fellow.

Prof. Eui-Cheol Shin received his M.D. (1996) and Ph.D. (2001) from Yonsei University College of Medicine, Seoul, Republic of Korea, and his postdoctoral training from NIDDK, National Institutes of Health, Bethesda, Maryland, USA. Then he joined the Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, the Republic of Korea, in 2007, where he is currently a professor. His laboratory researches T cell responses in human viral disease and cancer. In particular, they now focus on ‘T cell-mediated immunopathogenesis,‘ ‘senescence of T cells,’ ‘reinvigoration of exhausted T cells,‘ ‘human immune monitoring,’ and ‘immune responses in SARS-CoV-2 infection and COVID-19’. Prof. Shin was elected as a member of The Korea Academy of Science and Technology in 2019.

Dr. Pai Jin Keon graduated from the Department of Biochemistry of Yonsei University in 1974 and received Ph.D. at the School of Pharmacy, the University of Wisconsin-Madison, in 1982. Since 1986 Dr. Pai has worked as a senior researcher at Schering-Plough in the United States for 24 years.
Since returning to Korea in 2008, he served as Executive Director of R&D, JW Pharmaceutical Co., Ltd., and CEO of C&C New Drug Development Research Institute. Dr. Pai was essential in introducing open innovation at Handok Pharmaceuticals for five years. After retiring at Handok, he was the Vice President of the Abnoa Research Institute in Korea. He currently serves as the Senior Vice President of Innocure Therapeutics and an in-house board director. He is also helping startups as the head of the Technology Assessment Team at the WoojungBio New Drug Discovery Cluster.
He published 'Development of New Medicine to Save People' and 'Basic Story of Saving People in COVID-19' and has written more than 400 columns for ordinary people.